Skip to main content

Facioscapulohumeral Muscular Dystrophy (FSHD)

0
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Fulcrum Therapeutics
3 programs
LosmapimodPHASE_21 trial
Losmapimod oral tabletPHASE_21 trial
LosmapimodPHASE_31 trial
Active Trials
NCT04264442Terminated76Est. Nov 2024
NCT04003974Completed80Est. Jan 2021
NCT05397470Terminated260Est. Nov 2024
aTyr Pharma
aTyr PharmaSAN DIEGO, CA
1 program
ATYR1940PHASE_1_21 trial
Active Trials
NCT02603562Completed8Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fulcrum TherapeuticsLosmapimod
Fulcrum TherapeuticsLosmapimod
Fulcrum TherapeuticsLosmapimod oral tablet
aTyr PharmaATYR1940

Clinical Trials (4)

Total enrollment: 424 patients across 4 trials

NCT05397470Fulcrum TherapeuticsLosmapimod

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Start: Jun 2022Est. completion: Nov 2024260 patients
Phase 3Terminated
NCT04264442Fulcrum TherapeuticsLosmapimod

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Start: Feb 2020Est. completion: Nov 202476 patients
Phase 2Terminated
NCT04003974Fulcrum TherapeuticsLosmapimod oral tablet

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: Aug 2019Est. completion: Jan 202180 patients
Phase 2Completed
NCT02603562aTyr PharmaATYR1940

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

Start: Mar 2016Est. completion: Dec 20168 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.